Clinical Trial Update: A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral AKST4290 for moderately to severely diabetic retinopathy was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Retinopathy

Drugs mentioned

• AKST4290

Snippet

Sponsor: Alkahest, Inc. | Conditions: Diabetic Retinopathy | Phase 2 | Status: TERMINATED | Results posted: 2023-11-01